Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505739 · ClinicalTrials.gov registry record · Phase 2
Mifepristone for Patients With Endometrial Cancer and LGESS
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00505739: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00505739 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505739, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS). 2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient population. 3. To evaluate at a tissue level the effect of Mifepristone on estrogen and progesterone receptors post treatment and to evaluate other markers that may reflect effects of Mifepristone on cancer cell growth. 4. To evaluate the effect of the agent and dosing schedule on the patient's quality of life.
Interventions
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2001-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505739
The ClinicalTrials.gov registry entry for NCT00505739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mifepristone is the first listed.
NCT00505739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505739 about?
NCT00505739 is a clinical study titled "Mifepristone for Patients With Endometrial Cancer and LGESS". Primary Objectives: 1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS). 2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient populat...
What is the current status of trial NCT00505739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2001-09. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00505739?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT00505739?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.